单臂可行性试验中输注白蛋白溶液可提高慢加急性肝衰竭患者的血清白蛋白水平
这项前瞻性多中心单臂开放标签可行性试验纳入英国10家医院79例急性失代偿或慢加急性肝衰竭且白蛋白低于30 g/L的患者,给予20%人血白蛋白溶液每日输注最多14天。主要终点为治疗期间每日血清白蛋白水平,68/79例患者达到白蛋白≥30 g/L至少占记录天数的三分之一;发生8例死亡和13例严重不良事件,独立数据监测委员会认为与预期一致。
要点
- 79例急性失代偿或慢加急性肝衰竭患者中68例达到血清白蛋白≥30 g/L至少占记录天数的三分之一。
- 75%的输注符合建议给药方案,平均治疗时长10.3天,累计输注104±678 mL。
- 发生8例死亡和13例严重不良事件,独立数据监测委员会认为与预期一致。
核心结论
- 在可行性试验中,输注人血白蛋白溶液可提高急性失代偿或慢加急性肝衰竭患者的血清白蛋白水平。
- 该给药方案在多中心可接受,并被独立数据监测委员会认为安全。
- 肾功能障碍患者预后差得到证实,而心血管或呼吸功能障碍患者结局良好,与直觉相反。
研究设计与样本
- 前瞻性多中心单臂开放标签可行性试验,纳入英国10家医院79例急性失代偿或慢加急性肝衰竭且白蛋白低于30 g/L的患者。
- 患者于2015年5月至12月期间根据血清白蛋白水平每日输注20%人血白蛋白溶液,持续14天或至出院。
- 主要终点为治疗期间每日血清白蛋白水平,若60%患者达到并维持血清白蛋白≥30 g/L至少占记录天数的三分之一则判定为成功。
主要发现
- 患者平均终末期肝病模型评分为20.9±6.6。
- 主要终点由79例患者中的68例达到。
- 75%的输注符合建议给药方案,平均治疗时长10.3天,累计输注104±678 mL。
- 发生8例死亡和13例严重不良事件,独立数据监测委员会认为与预期一致。
- 13例仅出现呼吸或心血管功能障碍的患者中12例在30天时存活,而3例出现肾功能障碍的患者中1例存活;仅记录到1例脑功能障碍。
关键数值与推荐
- 主要终点达标标准为60%患者达到并维持血清白蛋白≥30 g/L至少占记录天数的三分之一。
- 实际有68/79例患者达到白蛋白≥30 g/L至少占记录天数的三分之一。
- 入组条件为血清白蛋白低于30 g/L。
临床怎么用
- 作者认为该白蛋白给药方案在多中心可接受且被独立数据监测委员会认为安全。
- 作者指出肾功能障碍患者预后差得到证实。
- 作者指出严重脑病似乎被明显漏报,提示病房评估这些参数无法以足够准确性记录,不能用作3期试验的主要结局。
局限性
- 原文指出严重脑病似乎被明显漏报,病房评估这些参数无法以足够准确性记录,不能用作3期试验的主要结局。
- 原文指出心血管或呼吸功能障碍患者结局良好与直觉相反。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Infections are life-threatening to patients with acute decompensation and acute-on-chronic liver failure (AD/ACLF). Patients with AD/ACLF have prostaglandin E2-mediated immune suppression, which can be reversed by administration of albumin; infusion of 20% human albumin solution (HAS) might improve outcomes of infections. We performed a feasibility study to determine optimal trial design, assess safety, and validate laboratory assessments of immune function to inform design of a phase 3 trial. METHODS: We performed a prospective multicenter, single-arm, open-label trial of 79 patients with AD/ACLF and levels of albumin lower than 30 g/L, seen at 10 hospitals in the United Kingdom from May through December 2015. Patients were given daily infusions of 20% HAS, based on serum levels, for 14 days or until discharge from the hospital. Rates of infection, organ dysfunction, and in-hospital mortality were recorded. The primary end point was daily serum albumin level during the treatment period. Success would be demonstrated if 60% achieved and maintained serum albumin levels at or above 30 g/L on at least one third of days with recorded levels. RESULTS: The patients' mean model for end-stage disease score was 20.9 ± 6.6. The primary end point (albumin ≥30 g/L on at least one third of days recorded) was achieved by 68 of the 79 patients; 75% of administrations were in accordance with suggested dosing regimen. Mean treatment duration was 10.3 days (104 ± 678 mL administered). There were 8 deaths and 13 serious adverse events, considered by the independent data-monitoring committee to be consistent with those expected. Twelve of 13 patients that developed either respiratory or cardiovascular dysfunction (based on ward-based clinical definitions) as their only organ dysfunction were alive at 30 days compared with 1 of 3 that developed renal dysfunction. Only 1 case of brain dysfunction was recorded. CONCLUSIONS: In a feasibility trial, we found that administration of HAS increased serum levels of albumin in patients with AD/ACLF. The dosing regimen was acceptable at multiple sites and deemed safe by an independent data-monitoring committee. We also developed a robust system to record infections. The poor prognosis for patients with renal dysfunction was confirmed. However, patients with cardiovascular or respiratory dysfunction had good outcomes, which is counterintuitive. Severe encephalopathy appeared substantially under-reported, indicating that ward-based assessment of these parameters cannot be recorded with sufficient accuracy for use as a primary outcome in phase 3 trials. Trial registration no: EudraCT 2014-002300-24 and ISRCTN14174793.
引用
- China L, Skene SS, Shabir Z, et al. Administration of Albumin Solution Increases Serum Levels of Albumin in Patients With Chronic Liver Failure in a Single-Arm Feasibility Trial. Clin Gastroenterol Hepatol. 2017. PMID: 28911947. doi:10.1016/j.cgh.2017.09.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。